We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Inhibition of Cancer Growth by Vitamin D Requires Receptor Induction

By LabMedica International staff writers
Posted on 17 Feb 2009
A recent paper regarding the inhibitory effect of vitamin D on the growth of breast cancer cells highlighted the important role of the CCAAT-enhancer binding protein (C/EBP-alpha). More...
C/EBP proteins interact with the CCAAT (cytidine-cytidine-adenosine-adenosine-thymidine) nucleoside box motif, which is present in several gene promoters.

Investigators at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (Newark, USA) studied the effect of calcitriol, the active form of vitamin D, on breast cancer cells growing in tissue culture.

They reported in the January 30, 2009, online issue of The Journal of Biological Chemistry that C/EBP-alpha was induced by calcitriol (1,25(OH)2D3) and was a potent enhancer of vitamin D receptor transcription in MCF-7 breast cancer cells. C/EBP-alpha was not detected in MDA-MB-231 cells that were poorly responsive to calcitriol. Induction of vitamin D receptors was observed in MDA-MB-231 cells transfected with C/EBP-alpha, while knockdown of C/EBP-alpha in MCF-7 cells suppressed vitamin D receptors and reversed the antiproliferative effects of calcitriol. In other words, cancer cells that were unable to activate receptors for vitamin D were not inhibited by exposure to the vitamin.

"These results provide an important process in which the active form of vitamin D may work to reduce growth of breast cancer cells," said senior author Dr. Sylvia Christakos, professor of biochemistry and molecular biology at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School. "These studies provide a basis for the design of new anticancer agents that can target the protein as a candidate for breast cancer treatment."

Related Links:
University of Medicine and Dentistry of New Jersey-New Jersey Medical School



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.